• OPEN AN ACCOUNT
Indian Indices
Sensex
83,576.24 -604.72
( -0.72%)
Global Indices
Nasdaq
49,520.87 233.75
(0.47%)
Dow Jones
6,986.78 44.32
(0.64%)
Hang Seng
51,918.01 800.75
(1.57%)
Nikkei 225
10,123.15 78.46
(0.78%)
Forex
USD-INR
89.91 -0.02
(-0.02%)
EUR-INR
104.90 -0.20
(-0.19%)
GBP-INR
120.86 -0.43
(-0.35%)
JPY-INR
0.57 0.00
(-0.15%)

EQUITY - MARKET SCREENER

Bank of Baroda
Industry :  Banks - Public Sector
BSE Code
ISIN Demat
Book Value()
532134
INE028A01039
284.2472203
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
BANKBARODA
8.08
155373.58
EPS(TTM)
Face Value()
Div & Yield %
37.2
2
2.78
 

Pfizer gains after Q2 PAT rises 19% YoY
Nov 13,2025
On a standalone basis, net sales stood at Rs 642.34 crore, rising 9.1% year-on-year from Rs 588.59 crore in Q2 FY25 and 6.5% sequentially from Rs 603.05 crore in Q1 FY26.

Net profit (PAT) rose 19.4% YoY to Rs 189.02 crore, compared with Rs 158.35 crore in Q2 FY25, as current tax expense increased 9.4% to Rs 65.49 crore. Sequentially, PAT was down 1.4% from Rs 191.75 crore in Q1 FY26.

Profit before tax (PBT) climbed 18.7% YoY to Rs 255.37 crore, though slightly lower by 1.6% QoQ.

Total expenditure inched up 3.3% YoY and 4.9% QoQ to Rs 412.41 crore. Raw material costs declined 8.7% YoY to Rs 70 crore, while employee expenses fell 6% YoY to Rs 94.67 crore. Depreciation stood at Rs 14.28 crore, down 4.74% year-on-year, while interest expenses were steady at Rs 2.13 crore.

Net cash flow from operating activities stood at Rs 599.47 crore in H1 FY26, as against a cash flow of Rs 349.43 crore in H1 FY25.

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.